SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind BioNTech Investors of a Lead Plaintiff Deadline of March 12, 2024

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- Attention BioNTech SE ("BioNTech") (NASDAQ: BNTX) shareholders:

The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 30, 2022 and October 13, 2023.

If you suffered a loss on your investment in BioNTech, contact us about potential recovery by using the link below. There is no cost or obligation to you.

https://www.wongesq.com/pslra-1/biontech-class-action-submission-form/?prid=64625&wire=4

ABOUT THE ACTION: The class action against BioNTech includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) BioNTech overstated demand for and/or the commercial prospects of Comirnaty, the COVID-19 vaccine developed by the Company in collaboration with Pfizer ; (ii) the Company and/or Pfizer had accumulated excess inventory of raw materials for Comirnaty, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants that were produced at risk; (iii) accordingly, BioNTech was at an increased risk of recording significant inventory write-offs and other charges related to Comirnaty; and (iv) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

DEADLINE: March 12, 2024

Aggrieved BioNTech investors only have until March 12, 2024 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: [email protected] 

SOURCE The Law Offices of Vincent Wong

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED